Could CBD calm Alzheimer's agitation? new trial seeks answers

NCT ID NCT06014424

Recruiting now Symptom relief Sponsor: Sunnybrook Health Sciences Centre Source: ClinicalTrials.gov ↗

First seen Jan 30, 2026 · Last updated May 14, 2026 · Updated 12 times

Summary

This study tests whether cannabidiol (CBD) capsules can safely reduce agitation in people with Alzheimer's disease. About 40 participants aged 55 and older will receive either CBD or a placebo, then switch treatments to compare effects. The goal is to find a new way to ease distressing symptoms and identify biological markers that predict who benefits most.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Centre for Addiction and Mental Health
RECRUITING

Toronto, Ontario, Canada

Contact Email: •••••@•••••
London Health Sciences Centre
RECRUITING

London, Ontario, Canada

Contact Phone: •••-•••-•••• Email: •••••@•••••
Ontario Shores Centre for Mental Health Sciences
RECRUITING

Whitby, Ontario, L1N 5S9, Canada

Contact Email: •••••@•••••
Sunnybrook Health Sciences Centre
RECRUITING

Toronto, Ontario, M3H0A7, Canada

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
University of Calgary
RECRUITING

Calgary, Alberta, T2N 4N1, Canada

Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

ALZHEIMER DISEASE